- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01914445
Chromoendoscopy of the Colon After Oral Administration of Indigo Carmine
July 31, 2013 updated by: Hillel Yaffe Medical Center
The purpose of this study is to examine whether oral administration of Indigo Carmine together with Polyethylene Glycol (PEG), the usual colon preparatory solution, can be used instead of staining during the examination itself.
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
10
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Hadera, Israel, 38100
- Hillel Yaffe Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients suffering from Inflammatory Bowel Disease
- Patients under surveillance for Disease-Associated Lesions and Masses (DALM)
Exclusion Criteria:
- All others
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: Indigo Carmine
Indigo Carmine (2 mg per kilo) and 2nd half of PEG dose will be orally administered to patients prior to colonoscopy.
|
Oral administration of Indigo Carmine prior to colonoscopy
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Efficacy of Indigo Carmine during oral administration
Time Frame: One hour
|
The efficacy of Indigo Carmine in staining tissues to better characterize, delineate, and highlight the gastrointestinal mucosa will be determined during the colonoscopic examination.
Biopsies will be taken from suspicious lesions.
|
One hour
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Vitaly Verzhbitsky, MD, Hillel Yaffe Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2013
Primary Completion (ANTICIPATED)
December 1, 2013
Study Completion (ANTICIPATED)
December 1, 2013
Study Registration Dates
First Submitted
July 31, 2013
First Submitted That Met QC Criteria
July 31, 2013
First Posted (ESTIMATE)
August 2, 2013
Study Record Updates
Last Update Posted (ESTIMATE)
August 2, 2013
Last Update Submitted That Met QC Criteria
July 31, 2013
Last Verified
July 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HYMC-46-13
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Inflammatory Bowel Diseases
-
Cook Children's Health Care SystemNot yet recruitingIBD | IBD - Inflammatory Bowel Disease | IBD (Inflammatory Bowel Disease)United States
-
Ningbo Medical Center Lihuili HospitalRecruitingInflammatory Bowel Disease (IBD)China
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaRecruitingIBD - Inflammatory Bowel DiseaseItaly
-
Chang Kyun LeeChonnam National University Hospital; Kyungpook National University Hospital; Chung-Ang University Hosptial, Chung-Ang University College of Medicine and other collaboratorsRecruitingInflammatory Bowel Disease (IBD)Korea, Republic of
-
Xijing HospitalNot yet recruitingInflammatory Bowel Diseases (IBD)China
-
Assiut UniversityNot yet recruitingInflammatory Bowel Disease (IBD)
-
University of British ColumbiaCompletedInflammatory Bowel Disease 11Canada
-
University of ChicagoTerminatedInflammatory Bowel Disease (IBD)United States
-
University of Texas Southwestern Medical CenterEnrolling by invitationInflammatory Bowel Disease | Inflammatory Bowel Disease (IBD)United States
-
University Hospital, GrenobleInstitute for Advanced Biosciences (IAB), GrenobleNot yet recruitingInflammatory Bowel Disease (IBD)France
Clinical Trials on Indigo Carmine
-
Weill Medical College of Cornell UniversityCompletedBrain Tumors With Ill-defined MarginsUnited States
-
Karolinska University HospitalUnknownLymphocytic Colitis | Collagenous Colitis | Chronic DiarrhoeaSweden
-
Karolinska University HospitalUnknownUlcerative Colitis | Crohn's ColitisSweden
-
Walter BrunnerCompletedRectal NeoplasmsSwitzerland
-
Hospital Universitario de MóstolesCompletedColonic Polyp | Colonic Neoplasms | Colonic Cancer
-
The Leeds Teaching Hospitals NHS TrustUnknown
-
Changhai HospitalThe First Affiliated Hospital of Nanchang University; The Second Hospital of... and other collaboratorsNot yet recruitingSessile Serrated LesionChina
-
VA Office of Research and DevelopmentCompletedColorectal NeoplasmsUnited States
-
King's College Hospital NHS TrustCompletedInflammatory Bowel DiseaseUnited Kingdom
-
Hospital Universitari Vall d'Hebron Research InstituteNot yet recruitingPulmonary Embolism AcuteSpain